Discover trends, market shifts, and competitive outlooks for the opdivo (nivolumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Opdivo (nivolumab) Market In 2029?

The market for opdivo (nivolumab) has been experiencing considerable expansion in recent times. Its size is projected to increase from $7,709.49 million in 2024 to $8,335.54 million in 2025, with a compound annual growth rate (CAGR) of 8.1%. This surge over the historical period is attributable to the increasing occurrence of cancer, escalated spending on research and development capabilities, larger investment in health care facilities, growing incidence of non-small lung cancer, and an expansion in capital equipment healthcare expenditure.

The market size for Opdivo (Nivolumab) is anticipated to experience robust growth in the upcoming years, reaching a value of $11,281.56 million by 2029 with a CAGR of 7.9%. This projected growth through the forecast period is due to the increasing acceptance of immunotherapy, heightened awareness about its benefits, escalated healthcare spending on capital equipment, broader application of Nivolumab for several indications, and an increasing preference for immunotherapy treatments. Additionally, the forecast period is likely to witness product innovation, geographical market expansion, ongoing clinical trials, and a growing inclination towards personalized medicine, coupled with advancements in cancer research as the major trends.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Opdivo (nivolumab) Market?

The rise in occurrences of non-small lung cancer is anticipated to drive the expansion of the opdivo (nivolumab) market in the future. Accounting for about 85% of all lung cancer instances, non-small cell lung cancer (NSCLC) is the most prevalent type. The escalating frequency of non-small cell lung which is primarily due to elements like smoking, exposure to environmental hazards, gene alterations, and familial cancer history. Opdivo operates by impeding the PD-1 receptor on immune cells, thereby intensifying the body’s immune response to identify and combat cancer cells. For instance, in 2024, the American Cancer Society, a US health organization, noted that 234,580 fresh cases of lung cancer had been identified in the US, and 80% of those were non-small cell lung cancer (NSCLC), evidencing an increase compared to 2023 when 238,340 individuals were diagnosed with lung cancer. Consequently, the escalating frequency of non-small lung cancer is propelling the upward growth of the opdivo (nivolumab) market.

Which Key Market Segments Comprise the Opdivo (nivolumab) Market and Drive Its Revenue Growth?

The opdivo (nivolumab)market covered in this report is segmented –

1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL

2) By Dosage: Injection; Solution; Other Dosages

3) By Demographic: Adult; Pediatric

4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications

5) By End-User: Hospitals; Clinics; Other End Users

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19914&type=smp

Which Areas Are Leading Regions in the Opdivo (nivolumab) Market Expansion Across the Globe?

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering theOpdivo (nivolumab) Market Direction?

The primary trend in the opdivo (nivolumab) market revolves around the development of combination therapies to augment treatment effectiveness and extend its use across varied types of cancer. Combination strategies aim to tackle resistance mechanisms and deliver a broader range of treatment options for advanced cancer patients. For example, in October 2024, the US-based federal agency, Food and Drug Administration, sanctioned the use of Opdivo (nivolumab) in conjunction with platinum-doublet chemotherapy as an anticipatory treatment, succeeded by nivolumab as an adjuvant treatment following surgery for adults with resectable non-small cell lung cancer. This approval paves the way for utilizing Opdivo with platinum-doublet chemotherapy prior to surgery and as a standalone therapy post-surgery for patients devoid of known EGFR or ALK mutations.

View the full report here:

https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-

How Is the Opdivo (nivolumab) Market Conceptually Defined?

Opdivo (nivolumab) is a prescription medication that belongs to a class of drugs known as immune checkpoint inhibitors, specifically targeting programmed death-1 (PD-1) receptors. It is a type of immunotherapy used to treat various cancers by enhancing the body’s immune system to detect and destroy cancer cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19914

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model